OBSIDIAN – real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
OBSIDIAN – real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-07-17
DOI
10.1093/rheumatology/keab572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety evaluations of adalimumab for childhood chronic rheumatic diseases
- (2020) Ilaria Maccora et al. Expert Opinion On Drug Safety
- Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
- (2020) Cosimo Bruni et al. CLINICAL RHEUMATOLOGY
- Update on noninfectious uveitis in children and its treatment
- (2020) Ilaria Maccora et al. CURRENT OPINION IN RHEUMATOLOGY
- Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review
- (2020) Ji-Won Kim et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis
- (2020) Ilaria Maccora et al. RHEUMATOLOGY
- Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
- (2020) Tom W. J. Huizinga et al. Rheumatology and Therapy
- Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- (2019) Gionata Fiorino et al. DIGESTIVE AND LIVER DISEASE
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
- (2019) Sheila T. Angeles‐Han et al. ARTHRITIS CARE & RESEARCH
- Treatment of juvenile idiopathic arthritis
- (2019) Gabriella Giancane et al. CURRENT OPINION IN RHEUMATOLOGY
- Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review
- (2019) C Diener et al. Expert Opinion On Drug Safety
- The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases
- (2019) Jacqueline L. Hayworth et al. JOINT BONE SPINE
- Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation
- (2019) Cristina Guiotto et al. DIGESTIVE AND LIVER DISEASE
- Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7‐Year Interim Results
- (2019) Hermine I. Brunner et al. ARTHRITIS CARE & RESEARCH
- Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis – A comparison in a real-world national cohort
- (2019) Cătălin Codreanu et al. BIOLOGICALS
- Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
- (2018) Sang-Cheol Bae et al. CLINICAL RHEUMATOLOGY
- Use of Infliximab Biosimilar Versus Originator in a Paediatric United Kingdom Inflammatory Bowel Disease Induction Cohort
- (2018) Neil Chanchlani et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Switching from Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease is Feasible and Uneventful
- (2018) Lisa Gervais et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- The Science Behind Biosimilars
- (2018) S. Louis Bridges et al. Arthritis & Rheumatology
- Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis
- (2018) Michael E. Weinblatt et al. Arthritis & Rheumatology
- To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
- (2018) Bente Glintborg et al. ANNALS OF THE RHEUMATIC DISEASES
- Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus
- (2018) Alberto Martini et al. JOURNAL OF RHEUMATOLOGY
- Biologics in juvenile idiopathic arthritis: a narrative review
- (2017) Federica Vanoni et al. EUROPEAN JOURNAL OF PEDIATRICS
- Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease
- (2017) Joanna Sieczkowska-Golub et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
- (2017) Athimalaipet V. Ramanan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The process defines the product: what really matters in biosimilar design and production?
- (2017) Arnold G. Vulto et al. RHEUMATOLOGY
- 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
- (2017) Paul Emery et al. RHEUMATOLOGY
- Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
- (2017) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
- (2016) T. Constantin et al. JOURNAL OF RHEUMATOLOGY
- A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis
- (2015) Rubén Burgos-Vargas et al. ARTHRITIS CARE & RESEARCH
- Efficacy and Safety of Etanercept in Patients With the Enthesitis-Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double-Blind Study
- (2015) Gerd Horneff et al. Arthritis & Rheumatology
- Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
- (2014) Daniel J. Kingsbury et al. CLINICAL RHEUMATOLOGY
- Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years
- (2014) D. Windschall et al. RHEUMATOLOGY INTERNATIONAL
- Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
- (2013) Howard Lee AAPS Journal
- Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score
- (2013) Alessandro Consolaro et al. ANNALS OF THE RHEUMATIC DISEASES
- Prevalence and incidence of juvenile idiopathic arthritis: A systematic review
- (2013) Sigrid Thierry et al. JOINT BONE SPINE
- Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
- (2012) Tomoyuki Imagawa et al. CLINICAL RHEUMATOLOGY
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry
- (2008) G Horneff et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started